Gefinix 250 mg (Tablet)
Unit Price: ৳ 250.00 (3 x 10: ৳ 7,500.00)
Strip Price: ৳ 2,500.00
Medicine Details
Category | Details |
---|---|
Generic | Gefitinib |
Company | Beacon pharmaceuticals plc |
Indications
- First-line treatment for metastatic non-small cell lung cancer (NSCLC)
- Patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Pharmacology
- Reversibly inhibits kinase activity of wild-type and certain activating mutations of EGFR
- Prevents autophosphorylation of tyrosine residues
- Blocks EGFR-dependent proliferation
- Higher binding affinity for EGFR mutations than for wild-type EGFR
- Inhibits IGF and PDGF-mediated signaling
Dosage & Administration
- Recommended dose: 250 mg orally once daily with or without food
- Do not take a missed dose within 12 hours of the next dose
- Administration to patients who have difficulty swallowing solids: tablets should be immersed in water and stirred before consumption
Interaction
- CYP3A4 inducer increases metabolism and decreases plasma concentrations
- Strong CYP3A4 inhibitors decrease metabolism and increase plasma concentrations
Contraindications
- Known hypersensitivity to Gefitinib or any other components of the drug
Side Effects
- Interstitial Lung Disease
- Hepatotoxicity
- Gastrointestinal Perforation
- Severe or Persistent Diarrhea
- Ocular Disorders including Keratitis
- Bullous and Exfoliative Skin Disorders
Pregnancy & Lactation
- No adequate and well-controlled studies in pregnant women
- Potential hazard to fetus or risk for loss of pregnancy
- Not known whether excreted in human milk
- Advised to discontinue breast-feeding during treatment
Precautions & Warnings
- ILD occurrence in patients with worsening respiratory symptoms
- Hepatotoxicity requiring periodic liver function testing
- Gastrointestinal perforation
- Severe or persistent diarrhea
- Ocular disorders including keratitis
- Bullous and exfoliative skin disorders
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No clinical studies in patients with severe renal impairment
- Adverse reactions monitoring in patients with moderate and severe hepatic impairment
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store between 20-25°C
- Store in a cool and dry place, away from sunlight
- Keep out of the reach of children